July 10, 2019 / 11:07 AM / 11 days ago

Amneal Pharma slashes core earnings forecast on allergy shot supply issues

July 10 (Reuters) - Amneal Pharmaceuticals Inc on Wednesday cut its core earnings forecast for the year, citing uncertainty in supply of epinephrine auto-injectors amid a global shortage of the emergency allergy shots, including Mylan NV's EpiPen.

Amneal now expects full-year adjusted earnings before interest, tax, depreciation and amortization in the range $425 million to $475 million, compared with its previous forecast of $600 million to $650 million. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below